Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation

Blood

Volumn 104, Issue 5, 2004, Pages 1574-1577

  Srivastava, Alok ^a   Poonkuzhali, Balasubramanian ^a   Shaji, Ramachandran V ^a   George, Biju ^a   Mathews, Vikram ^a   Chandy, Mammen ^a   Krishnamoorthy, Rajagopal ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DRUG METABOLITE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; LYMPHOGLOBULINE; PHENYTOIN; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG CLEARANCE; ENDOTHELIUM CELL; GENE; GENETIC POLYMORPHISM; GENOTYPE; GSTM1 GENE; GSTT1 GENE; HUMAN; LIVER INJURY; LIVER SINUSOID; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE;

EID: 4444259109     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3778     Document Type: Article

References (32)

1. Wadleigh M, Ho V, Momtaz P, Rishardson P. Hepatic veno-occlusive disease- pathogenesis, diagnosis and treatment. Curr Opin Hematol. 2003;10:451-462.
2. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to the hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27-42.
3. Bearman SI. Avoiding hepatic veno-occlusive disease: what do we know and where are we going? Bone Marrow Transplant. 2001;27:1113-1120.
4. Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2003;32:79-87.
5. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol. 2000;64:281-291.
6. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute non-lymphocytic leukaemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-1353.
7. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036-2043.
8. DeLeve LD. Hepatic venoocclusive disease: a major complication of hematopoietic stem cell transplantation in cancer patients. Tumori. 2001;87:S28-S30.
9. Slattery JT, Sanders JE, Buckner CD, et al. Graft rejection and toxicity in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
10. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity and mortality following hematopoietic stem cell transplantation. Blood. 2003;101:2043-2048.
11. Hassan M, Ljungman P, Ringden O, et al. Effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy related toxicity. Bone Marrow Transplant. 2000;25:915-924.
12. Dirven HA, Van Ommen B, Van Bladeren PJ, et al. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol. 1996;9:351-360.
13. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases α, μ, and π. Drug Metabol Disp. 1996;24:1015-1019.
14. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996;56:3678-3681.
15. Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic difference in the prevalence of the homozygous deleted genotype of GST. Carcinogenesis. 1995;16:1243-1245.
16. Arruda VR, Grignolli CE, Gonclaves MS, et al. Prevalence of homozygosity for the deleted alleles of GSTM1 and GSTT1 among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Clin Genet. 1998;54:210-214.
17. DeLeve D, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60:143-154.
18. Poonkuzhali B, Srivastava A, Quernin MH, et al. Pharmacokinetics of oral busulphan in children with beta thalassemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:5-11.
19. Li CK, Yuen PM, Wong R, et al. Busulphan level and early mortality in thalassaemia patients after BMT. Bone Marrow Transplant. 1999;23:307-310.
20. Jones RJ, Lee KSK, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778-783.
21. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med. 1990;332:417-421.
22. Quernin MH, Poonkuzhali B, Medard Y, et al. High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol. J Chromatogr. 1999;721:147-152.
23. Heinzel G, Woloszezak R, Thoman P. Pharmacokinetic pharmacodynamic data analysis system for the PC. Stuttgart, Germany: Gustav Fischer; 1993.
24. Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay for total plasma homocysteine and cysteine in a clinical laboratory setting. Clin Chem. 1999;45:290-292.
25. Arand M, Mullbauer R, Hengstler J, et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the GSTM1 and GSTT1 polymorphisms. Anal Biochem. 1996;236:184-186.
26. Dean AG, Dean JA, Coulombier D, et al. Epi Info version 6: a word processing database and statistical program for epidemiology on microcomputers. Atlanta, GA: Centers for Disease Control and Prevention; 1994.
27. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol. 1996;14:1484-1494.
28. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic veno-occlusive disease. Hepatology. 1996;23:589-599.
29. Poonkuzhali B, Lapoumeroulie C, Shaji RV, et al. GSTM1 null genotype is associated with elevated GST α expression in children with beta thalassemia major [abstract]. Blood. 2002;100:4373b. Abstract 4373.
30. Ritler CA, Sperker B, Grube M, et al. Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol. 2002;137:1100-1106.
31. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol. 2001;37:593-598.
32. Garte S, Gaspari L, Alexandrie A-K, et al. Metabolic gene polymorphisms in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239-1248.